These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 11748582)

  • 21. Metastasis-related genes in prostate cancer.
    Bangma CH; Nasu Y; Ren C; Thompson TC
    Semin Oncol; 1999 Aug; 26(4):422-7. PubMed ID: 10482184
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vivo models of prostate cancer metastasis to bone.
    Singh AS; Figg WD
    J Urol; 2005 Sep; 174(3):820-6. PubMed ID: 16093963
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ovarian cancer G protein-coupled receptor 1, a new metastasis suppressor gene in prostate cancer.
    Singh LS; Berk M; Oates R; Zhao Z; Tan H; Jiang Y; Zhou A; Kirmani K; Steinmetz R; Lindner D; Xu Y
    J Natl Cancer Inst; 2007 Sep; 99(17):1313-27. PubMed ID: 17728215
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Collagen XXIII expression is associated with prostate cancer recurrence and distant metastases.
    Banyard J; Bao L; Hofer MD; Zurakowski D; Spivey KA; Feldman AS; Hutchinson LM; Kuefer R; Rubin MA; Zetter BR
    Clin Cancer Res; 2007 May; 13(9):2634-42. PubMed ID: 17473194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival.
    Cheville JC; Tindall D; Boelter C; Jenkins R; Lohse CM; Pankratz VS; Sebo TJ; Davis B; Blute ML
    Cancer; 2002 Sep; 95(5):1028-36. PubMed ID: 12209687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity.
    Hua D; Liu MY; Cheng ZD; Qin XJ; Zhang HM; Chen Y; Qin GJ; Liang G; Li JN; Han XF; Liu DX
    Mol Immunol; 2009 Sep; 46(15):2876-84. PubMed ID: 19643479
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostate cancer biomarkers: a current perspective.
    Kumar-Sinha C; Rhodes DR; Yu J; Chinnaiyan AM
    Expert Rev Mol Diagn; 2003 Jul; 3(4):459-70. PubMed ID: 12877385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
    Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
    Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome.
    Yu J; Yu J; Rhodes DR; Tomlins SA; Cao X; Chen G; Mehra R; Wang X; Ghosh D; Shah RB; Varambally S; Pienta KJ; Chinnaiyan AM
    Cancer Res; 2007 Nov; 67(22):10657-63. PubMed ID: 18006806
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor cell-microenvironment interaction models coupled with clinical validation reveal CCL2 and SNCG as two predictors of colorectal cancer hepatic metastasis.
    Hu H; Sun L; Guo C; Liu Q; Zhou Z; Peng L; Pan J; Yu L; Lou J; Yang Z; Zhao P; Ran Y
    Clin Cancer Res; 2009 Sep; 15(17):5485-93. PubMed ID: 19706805
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The importance of determining the aggressiveness of prostate cancer using serum and tissue molecular markers.
    Kehinde EO; Maghrebi MA; Anim JT
    Can J Urol; 2008 Apr; 15(2):3967-74. PubMed ID: 18405443
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel lipogenic enzyme ELOVL7 is involved in prostate cancer growth through saturated long-chain fatty acid metabolism.
    Tamura K; Makino A; Hullin-Matsuda F; Kobayashi T; Furihata M; Chung S; Ashida S; Miki T; Fujioka T; Shuin T; Nakamura Y; Nakagawa H
    Cancer Res; 2009 Oct; 69(20):8133-40. PubMed ID: 19826053
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy.
    Haram KM; Peltier HJ; Lu B; Bhasin M; Otu HH; Choy B; Regan M; Libermann TA; Latham GJ; Sanda MG; Arredouani MS
    Prostate; 2008 Oct; 68(14):1517-30. PubMed ID: 18668517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heterogeneous expression of MAGE-A genes in occult disseminated tumor cells: a novel multimarker reverse transcription-polymerase chain reaction for diagnosis of micrometastatic disease.
    Kufer P; Zippelius A; Lutterbüse R; Mecklenburg I; Enzmann T; Montag A; Weckermann D; Passlick B; Prang N; Reichardt P; Dugas M; Köllermann MW; Pantel K; Riethmüller G
    Cancer Res; 2002 Jan; 62(1):251-61. PubMed ID: 11782385
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blood biomarkers for prostate cancer detection and prognosis.
    Shariat SF; Karam JA; Roehrborn CG
    Future Oncol; 2007 Aug; 3(4):449-61. PubMed ID: 17661720
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostate targeting: PSP94 gene promoter/enhancer region directed prostate tissue-specific expression in a transgenic mouse prostate cancer model.
    Gabril MY; Onita T; Ji PG; Sakai H; Chan FL; Koropatnick J; Chin JL; Moussa M; Xuan JW
    Gene Ther; 2002 Dec; 9(23):1589-99. PubMed ID: 12424611
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Gene expression profiling in prostatic cancer].
    Ernst T; Hergenhahn M; Kenzelmann M; Cohen CD; Ikinger U; Kretzler M; Hollstein M; Gröne HJ
    Verh Dtsch Ges Pathol; 2002; 86():165-75. PubMed ID: 12647366
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival.
    Kristiansen G; Pilarsky C; Wissmann C; Kaiser S; Bruemmendorf T; Roepcke S; Dahl E; Hinzmann B; Specht T; Pervan J; Stephan C; Loening S; Dietel M; Rosenthal A
    J Pathol; 2005 Feb; 205(3):359-76. PubMed ID: 15532095
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular changes in prostatic cancer.
    Bott SR; Arya M; Shergill IS; Williamson M
    Surg Oncol; 2005 Aug; 14(2):91-104. PubMed ID: 15993579
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer.
    Polnaszek N; Kwabi-Addo B; Peterson LE; Ozen M; Greenberg NM; Ortega S; Basilico C; Ittmann M
    Cancer Res; 2003 Sep; 63(18):5754-60. PubMed ID: 14522896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.